These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35664555)

  • 1. Lung toxicity of lomustine in the treatment of progressive gliomas.
    Seliger C; Nürnberg C; Wick W; Wick A
    Neurooncol Adv; 2022; 4(1):vdac068. PubMed ID: 35664555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation.
    Kim SH; Yoo H; Chang JH; Kim CY; Chung DS; Kim SH; Park SH; Lee YS; Yang SH
    J Korean Med Sci; 2018 Jun; 33(24):e167. PubMed ID: 29892208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
    Walbert T; Gilbert MR; Groves MD; Puduvalli VK; Yung WK; Conrad CA; Bobustuc GC; Colman H; Hsu SH; Bekele BN; Qiao W; Levin VA
    J Neurooncol; 2011 Apr; 102(2):273-80. PubMed ID: 20652724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reirradiation and lomustine in patients with relapsed high-grade gliomas.
    Arcicasa M; Roncadin M; Bidoli E; Dedkov A; Gigante M; Trovò MG
    Int J Radiat Oncol Biol Phys; 1999 Mar; 43(4):789-93. PubMed ID: 10098434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
    Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
    J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial.
    Patil VM; Menon N; Chatterjee A; Tonse R; Choudhari A; Mahajan A; Puranik AD; Epari S; Jadhav M; Pathak S; Peelay Z; Walavalkar R; Muthuluri HK; Ravi Krishna M; Chandrasekharan A; Pande N; Gupta T; Banavali S; Jalali R
    EClinicalMedicine; 2022 Jul; 49():101449. PubMed ID: 35747192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
    Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
    Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case series of salvage CCNU in high-grade glioma who have previously received temozolomide from a tertiary care institute in Mumbai.
    Patil VM; Abhinav R; Tonse R; Epari S; Gupta T; Jalali R
    Indian J Cancer; 2016; 53(4):558-561. PubMed ID: 28485350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
    Stritzelberger J; Distel L; Buslei R; Fietkau R; Putz F
    Clin Transl Oncol; 2018 Apr; 20(4):508-516. PubMed ID: 28825189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide.
    Glas M; Happold C; Rieger J; Wiewrodt D; Bähr O; Steinbach JP; Wick W; Kortmann RD; Reifenberger G; Weller M; Herrlinger U
    J Clin Oncol; 2009 Mar; 27(8):1257-61. PubMed ID: 19188676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.
    Chamberlain MC
    J Neurooncol; 2015 Apr; 122(2):329-38. PubMed ID: 25563816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
    Kaltsas GA; Mukherjee JJ; Isidori A; Kola B; Plowman PN; Monson JP; Grossman AB; Besser GM
    Clin Endocrinol (Oxf); 2002 Aug; 57(2):169-83. PubMed ID: 12153595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.
    Cordonnier C; Vernant JP; Mital P; Lange F; Bernaudin JF; Rochant H
    Cancer; 1983 May; 51(10):1814-8. PubMed ID: 6572542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic evaluation of low-grade gliomas in adults before and after treatment with CCNU alone.
    Kaloshi G; Roci E; Rroji A; Ducray F; Petrela M
    J Neurosurg; 2015 Nov; 123(5):1244-6. PubMed ID: 26115464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How did lomustine become standard of care in recurrent glioblastoma?
    Weller M; Le Rhun E
    Cancer Treat Rev; 2020 Jul; 87():102029. PubMed ID: 32408220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of the treatment of children with recurrent gliomas with lomustine and vincristine.
    Lefkowitz IB; Packer RJ; Sutton LN; Siegel KR; Bruce DA; Evans AE; Schut L
    Cancer; 1988 Mar; 61(5):896-902. PubMed ID: 3338054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas.
    Jakacki RI; Jamison C; Mathews VP; Heilman DK; Dropcho E; Cornetta K; Macdonald DR; Williams DA
    Med Pediatr Oncol; 1998 Dec; 31(6):483-90. PubMed ID: 9835900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group.
    J Neurosurg; 1981 Jul; 55(1):27-31. PubMed ID: 7017081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.
    Yamamuro S; Takahashi M; Satomi K; Sasaki N; Kobayashi T; Uchida E; Kawauchi D; Nakano T; Fujii T; Narita Y; Kondo A; Wada K; Yoshino A; Ichimura K; Tomiyama A
    Cancer Sci; 2021 Nov; 112(11):4736-4747. PubMed ID: 34536314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restrictive lung disease following treatment for malignant brain tumors: a potential late effect of craniospinal irradiation.
    Jakacki RI; Schramm CM; Donahue BR; Haas F; Allen JC
    J Clin Oncol; 1995 Jun; 13(6):1478-85. PubMed ID: 7751895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.